Table 2

Summary of curve fit parameters from results of experiments illustrated in Fig. 4

DrugpEC50EmaxDRUG/Emax 5-HTSlope factorn
IPAAIPAAIPAA
nm
5-HT7.43  ± 0.11 (37)7.34  ± 0.10 (46)1.01.01.20  ± 0.081.58  ± 0.249
Bufotenin6.50  ± 0.10 (318)6.33  ± 0.08 (468)0.78  ± 0.041.08  ± 0.061.64  ± 0.220.97  ± 0.15
(±)-DOI6.72  ± 0.11 (192)6.8  ± 0.09 (158)0.61  ± 0.070.97  ± 0.081.26  ± 0.121.01  ± 0.125
d-LSD7.80  ± 0.19 (16)8.11  ± 0.22 (8)0.17  ± 0.020.39  ± 0.061.01  ± 0.291.26  ± 0.459
Quipazine5.89  ± 0.02 (1.29 μ m) 6.06  ± 0.30 (0.87 μ m) 0.89  ± 0.120.59  ± 0.071.34  ± 0.101.29  ± 0.245
TFMPP6.34  ± 0.05 (457)6.48  ± 0.17 (490)1.02  ± 0.130.59  ± 0.071.36  ± 0.191.16  ± 0.165